Lung, Phase II
A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Volunteers
Health Professionals
What is the purpose of this trial?
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Clarice Grens
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- James Newman, MD
- Johanna LaSala, MD
- John Glendening
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Kert Sabbath, MD, FACP
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cohenuram, MD
- Robert Matera, MD
- Roy S. Herbst, MD, PhD
- Sarah Carlson
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Sharynn Hall, MD, PhD
- So Yeon Kim, MD
- Stacey LaRosa
- Su Hsien Lim, MD
- Vanna Dest
- Victor Chang, MD
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Last Updated12/10/2025
- Study HIC#2000041307